This CIBMTR (Center for International Blood and Marrow Transplant Research) study analyzed outcomes of 1,248 patients age ≥40 years undergoing reduced-intensity or non-myeloablative hematopoietic cell transplantation (HCT) for aggressive (n=668) or indolent (n=580) non-Hodgkin lymphoma (NHL). One-year relapse, acute and chronic GVHD, and non-relapse mortality (NRM) were comparable among the three age cohorts studied: 40-54 years, 55-64 years, and ≥65 years. Three-year overall survival (OS) was significantly lower in the older cohorts (54%, 40%, and 39%, respectively; p<0.0001). Age ≥55 years, HLA mismatch, and Karnofsky Performance Status <80 adversely affected NRM, progression-free survival, and OS. The authors concluded that "even for patients age ≥55 years, OS still approached 40% at 3 years, suggesting that HCT affects long-term remission and remains underused in qualified older patients with NHL."
McClune BL, et al. Biol Blood Marrow TransplantChoose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Encouraging Progression-Free Survival in HCT for Older NHL Patients
Apr 2014